金城医药
(300233)
| 流通市值：56.71亿 | | | 总市值：58.81亿 |
| 流通股本：3.70亿 | | | 总股本：3.84亿 |
| 报告期 | 2023-12-31 | 2023-09-30 | 2023-06-30 | 2023-03-31 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 一、营业总收入 | 3,538,312,459.65 | 2,568,752,667.57 | 1,705,293,296.69 | 829,526,542 |
| 营业收入 | 3,538,312,459.65 | 2,568,752,667.57 | 1,705,293,296.69 | 829,526,542 |
| 二、营业总成本 | 3,293,667,808.57 | 2,386,749,531.4 | 1,570,483,289.96 | 765,199,920.75 |
| 营业成本 | 1,991,127,087.91 | 1,481,237,371.13 | 969,720,965.31 | 475,423,314.44 |
| 税金及附加 | 36,155,248.75 | 28,097,165.92 | 18,305,243.48 | 9,061,715.28 |
| 销售费用 | 680,647,573.8 | 489,839,831.89 | 315,565,703.59 | 150,312,138.72 |
| 管理费用 | 390,750,791.04 | 256,459,465.98 | 184,252,986.45 | 93,935,166.62 |
| 研发费用 | 184,708,538.25 | 121,823,184.36 | 76,204,151.74 | 28,502,407.61 |
| 财务费用 | 10,278,568.82 | 9,292,512.12 | 6,434,239.39 | 7,965,178.08 |
| 其中:利息费用 | 24,924,241.76 | 19,192,178.59 | 13,470,866.87 | 6,674,810.48 |
| 其中:利息收入 | 14,592,685.12 | 9,442,987.34 | 6,048,361.31 | 3,326,254.19 |
| 加:公允价值变动收益 | -81,540.57 | -13,411.7 | -264,453.95 | -334,685.44 |
| 加:投资收益 | 590,132.95 | -70,366.52 | -333,115.14 | -16,391.91 |
| 资产处置收益 | -2,156,299.76 | -2,611,874.47 | -2,840,726.18 | -374,726.61 |
| 资产减值损失(新) | -46,542,833.7 | -18,541,487.6 | -7,484,141.49 | -48,413.87 |
| 信用减值损失(新) | -4,807,335.75 | -1,839,142.59 | -987,392.27 | -1,405,326.19 |
| 其他收益 | 34,202,442.64 | 16,589,485.47 | 11,274,006.5 | 6,600,474.57 |
| 营业利润平衡项目 | 0 | 0 | 0 | 0 |
| 四、营业利润 | 225,849,216.89 | 175,516,338.76 | 134,174,184.2 | 68,747,551.8 |
| 加:营业外收入 | 983,971.32 | 773,540.77 | 725,990.63 | 654,021.97 |
| 减:营业外支出 | 1,425,648.26 | -11,497.86 | -792,177.72 | -835,148.4 |
| 利润总额平衡项目 | 0 | 0 | 0 | 0 |
| 五、利润总额 | 225,407,539.95 | 176,301,377.39 | 135,692,352.55 | 70,236,722.17 |
| 减:所得税费用 | 32,096,540.84 | 29,646,354.21 | 24,919,791.7 | 15,357,053.2 |
| 六、净利润 | 193,310,999.11 | 146,655,023.18 | 110,772,560.85 | 54,879,668.97 |
| 持续经营净利润 | 193,310,999.11 | 146,655,023.18 | 110,772,560.85 | 54,879,668.97 |
| 归属于母公司股东的净利润 | 174,709,358.21 | 132,480,355.98 | 101,709,417.13 | 50,154,655.33 |
| 少数股东损益 | 18,601,640.9 | 14,174,667.2 | 9,063,143.72 | 4,725,013.64 |
| (一)基本每股收益 | 0.45 | 0.34 | 0.26 | 0.13 |
| (二)稀释每股收益 | 0.45 | 0.34 | 0.26 | 0.13 |
| 八、其他综合收益 | 1,705,202.58 | 7,056,674.1 | 7,056,674.1 | 5,511,232.38 |
| 归属于母公司股东的其他综合收益 | 1,705,202.58 | 7,056,674.1 | 7,056,674.1 | 5,511,232.38 |
| 九、综合收益总额 | 195,016,201.69 | 153,711,697.28 | 117,829,234.95 | 60,390,901.35 |
| 归属于母公司股东的综合收益总额 | 176,414,560.79 | 139,537,030.08 | 108,766,091.23 | 55,665,887.71 |
| 归属于少数股东的综合收益总额 | 18,601,640.9 | 14,174,667.2 | 9,063,143.72 | 4,725,013.64 |
| 公告日期 | 2024-03-29 | 2023-10-25 | 2023-08-19 | 2023-04-27 |
| 审计意见(境内) | 标准无保留意见 | | | |